NextGen 2024: Weaning meds when disease is controlled Session Part 1

NextGen 2024: Weaning meds when disease is controlled Session Part 1

@SJIA_Foundation

8 Followers

2 weeks ago 101

Science #stillsdisease #sjiafoundation #sjia #curesjia

NextGen 2024: Weaning meds when disease is controlled Session Part 1

@SJIA_Foundation2 weeks ago

Biomarker-Guided Treatment-And-Stop-Strategy for
Recombinant IL-1Receptor Antagonist (anakinra) i…

1/17

sJIA treatment
2. Nigrovic Arthritis Rheum 2014
• Biological treatment targeting the IL1 (anakin…

2/17

3. Vastert et al. Arthritis Rheum 2014,
4. Ter Haar et al. Arthritis Rheum 2019
Utrecht protocol…

3/17

• New-onset therapy naïve SJIA patients (PRINTO criteria6
)
• 6 centers in the Netherlands betwee…

4/17

Baseline cohort characteristics
Total number of participants 66
Number of participants interventi…

5/17

• CID after 3 months of rIL-1RA mono-therapy
• National multicenter setting = historic single cen…

6/17

Conclusions
• The Utrecht protocol, starting rIL-1RA early as first-line treatment in new-onset SJ…

7/17

How do we make use of all datapoints?

8/17

9/17

10/17

11/17

Non-linear mixed effects modeling

12/17

Cytokine modeling

13/17

Macrophage Activation Syndrome
• 17% (11/66) of patients developed
MAS in the follow-up of ESTIS…

14/17

Sytze De Roock
Gerda Den Engelsman
Marc Jansen
Johannes Roth Joost Swart
Thomas Vogl Petra Hiss…

15/17

16/17

Anakinra side-effects:
Local reaction at injection site (redness, itching)
generally, appear with…

17/17

@SJIA_Foundation

Drag Me

Comments 0 Info

NextGen 2024: Weaning meds when disease is controlled Session Part 1

@SJIA_Foundation

Presentation from Dr. Bas Vastert: Biomarker-Guided Treatment-And-Stop_Strategy for Recombinat IL-1Receptor Antagonist (anakinra) in systemic Juvenile Idiopathic Arthritis

Science

#stillsdisease #sjiafoundation #sjia #curesjia

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.